KIT-Mutant Melanoma: Understanding the Pathway to Personalized Therapy.
Cancers (Basel). 2025;17(22):ePub - PMID: 41301010 - PMCID: PMC12650433 - DOI: 10.3390/cancers17223644
Mendelian randomization analysis provides insights into the relationship between inflammatory bowel disease and skin cancer.
Systemic Therapies for Metastatic Melanoma.
Dermatol Clin. 2025;43(3):483-494 - PMID: 40581428 - DOI: 10.1016/j.det.2025.03.004
Acral Melanoma: A Review of Its Pathogenesis, Progression, and Management.
Recent progress in cancer vaccines and nanovaccines.
Biomaterials. 2024;314:122856 - PMID: 39366184 - DOI: 10.1016/j.biomaterials.2024.122856
Update on the Pathogenesis of Keloid Formation.
JID Innov. 2024;4(6):100299 - PMID: 39247523 - PMCID: PMC11378114 - DOI: 10.1016/j.xjidi.2024.100299
ATLAS: A positive, high-yield review of patient symptoms most significantly associated with melanoma recurrence.
J Am Acad Dermatol. 2024;91(6):1118-1124 - PMID: 39197498 - DOI: 10.1016/j.jaad.2024.07.1516
Differential time series analysis shows deceleration in melanoma mortality prior to the widespread use of highly effective therapies.
J Am Acad Dermatol. 2024;91(5):872-879 - PMID: 39038555 - PMCID: PMC11653201 - DOI: 10.1016/j.jaad.2024.07.1457
Fabrication and functional validation of a hybrid biomimetic nanovaccine (HBNV) against Kit K641E -mutant melanoma.
Bioact Mater. 2024;46:347-364 - PMID: 39834347 - PMCID: PMC11742834 - DOI: 10.1016/j.bioactmat.2024.12.023
Analysis of Variants Induced by Combined Ex Vivo Irradiation and In Vivo Tumorigenesis Suggests a Role for the ZNF831 p.R1393Q Variant in Cutaneous Melanoma Development.
J Invest Dermatol. 2024;145(7):1728-1739.e7 - PMID: 39675662 - DOI: 10.1016/j.jid.2024.08.042
Lentigo Maligna Part II: Management.
J Am Acad Dermatol. 2024;93(6):1399-1410 - PMID: 39447752 - DOI: 10.1016/j.jaad.2024.07.1534
Lentigo Maligna Part I: Epidemiology, Risk Factors, and Diagnosis.
J Am Acad Dermatol. 2024;93(6):1383-1396 - PMID: 39442885 - DOI: 10.1016/j.jaad.2024.09.065
Molecular Analysis of Murine KitK641E Melanoma Progression.
JID Innov. 2024;4(3):100266 - PMID: 38585193 - PMCID: PMC10995915 - DOI: 10.1016/j.xjidi.2024.100266
Multiple de novo spitzoid nevi arising within a specific red tattoo ink.
JAAD Case Rep. 2024;46:78-80 - PMID: 38577501 - PMCID: PMC10992272 - DOI: 10.1016/j.jdcr.2024.02.012
Germline cancer susceptibility in individuals with melanoma.
J Am Acad Dermatol. 2024;91(2):265-272 - PMID: 38513832 - DOI: 10.1016/j.jaad.2023.11.070
Geotemporal Analysis of Melanoma Incidence and Mortality Identifies Distinct Clusters of Trends within the United States Between 2001 and 2019.
J Invest Dermatol. 2024;145(2):393-399.e1 - PMID: 38981567 - PMCID: PMC11704087 - DOI: 10.1016/j.jid.2024.05.032
Keratinocytic skin cancers-Update on the molecular biology.
Cancer. 2023;129(6):836-844 - PMID: 36645692 - DOI: 10.1002/cncr.34635
Ultrasound-guided supraclavicular block versus Bier block for emergency reduction of upper limb injuries: a protocol for an open-label, non-inferiority, randomised controlled trial.
Acquired brachial cutaneous dyschromatosis.
JAAD Case Rep. 2023;37:110-113 - PMID: 37396486 - PMCID: PMC10314224 - DOI: 10.1016/j.jdcr.2023.05.007
Development and validation of time-to-event models to predict metastatic recurrence of localized cutaneous melanoma.
J Am Acad Dermatol. 2023;90(2):288-298 - PMID: 37797836 - PMCID: PMC10843255 - DOI: 10.1016/j.jaad.2023.08.105
Mendelian Randomization Analysis reveals Inverse Genetic Risks between Skin Cancers and Vitiligo.
JID Innov. 2023;3(6):100217 - PMID: 38034848 - PMCID: PMC10685305 - DOI: 10.1016/j.xjidi.2023.100217
DNA promoter hypermethylation of melanocyte lineage genes determines melanoma phenotype.
New Insights into Melanoma Tumor Syndromes.
Resilience of melanoma diagnostics at a tertiary-care hospital during the SARS-CoV-2 pandemic.
Melanoma classification and management in the era of molecular medicine.
Dermatol Clin. 2022;41(1):49-63 - PMID: 36410983 - DOI: 10.1016/j.det.2022.07.017
Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping.
J Invest Dermatol. 2022;143(5):842-853.e6 - PMID: 36529262 - DOI: 10.1016/j.jid.2022.03.039
Recognition, Staging, and Management of Melanoma.
Med Clin North Am. 2021;105(4):643-661 - PMID: 34059243 - DOI: 10.1016/j.mcna.2021.04.005
Effect of the COVID-19 Pandemic on Delayed Skin Cancer Services.
Dermatol Clin. 2021;39(4):627-637 - PMID: 34556252 - PMCID: PMC8162820 - DOI: 10.1016/j.det.2021.05.015
The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma.
J Invest Dermatol. 2021;141(8):2018-2027.e4 - PMID: 33745909 - PMCID: PMC8316294 - DOI: 10.1016/j.jid.2020.12.035
Patient-identified early clinical warning signs of nodular melanoma: a qualitative study.
The State of Melanoma: Emergent Challenges and Opportunities.
Clin Cancer Res. 2021;27(10):2678-2697 - PMID: 33414132 - PMCID: PMC8127340 - DOI: 10.1158/1078-0432.CCR-20-4092
Oncogenic KIT Induces Replication Stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma.
J Invest Dermatol. 2021;142(5):1413-1424.e6 - PMID: 34687746 - DOI: 10.1016/j.jid.2021.07.188
KIT and Melanoma: Biological Insights and Clinical Implications.
Yonsei Med J. 2020;61(7):562-571 - PMID: 32608199 - PMCID: PMC7329741 - DOI: 10.3349/ymj.2020.61.7.562
A Case of Nivolumab-Induced Cutaneous Toxicity with Multiple Morphologies.
Dermatopathology (Basel). 2020;6(4):255-259 - PMID: 32232031 - PMCID: PMC7098352 - DOI: 10.1159/000505353
Hypoxia and HIF-1α Regulate Collagen Production in Keloids.
J Invest Dermatol. 2020;140(11):2157-2165 - PMID: 32315657 - DOI: 10.1016/j.jid.2020.01.036
Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition.
J Invest Dermatol. 2020;141(5):1317-1324.e1 - PMID: 33159968 - DOI: 10.1016/j.jid.2020.06.041
Surgical delay and mortality for primary cutaneous melanoma.
J Am Acad Dermatol. 2020;84(4):1089-1091 - PMID: 32711092 - PMCID: PMC7375294 - DOI: 10.1016/j.jaad.2020.07.078
A geographically based cross-sectional analysis of SPOT me skin cancer screening data.
J Am Acad Dermatol. 2020;84(3):809-810.e3 - PMID: 32534079 - PMCID: PMC9469797 - DOI: 10.1016/j.jaad.2020.06.014
Burden of unique and low prevalence somatic mutations correlates with cancer survival.
BRCA1-associated protein (BAP1)-inactivated melanocytic tumors.
J Cutan Pathol. 2019;46(12):965-972 - PMID: 31233225 - DOI: 10.1111/cup.13530
Classifying Melanoma by TERT Promoter Mutational Status.
J Invest Dermatol. 2019;140(2):390-394.e1 - PMID: 31425705 - PMCID: PMC6983338 - DOI: 10.1016/j.jid.2019.06.149
Selective uveal melanoma inhibition with calcium channel blockade.
The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma.
Cell Rep. 2019;27(12):3573-3586.e7 - PMID: 31216476 - DOI: 10.1016/j.celrep.2019.05.069
Impact of electric scooters to a tertiary emergency department: 8-week review after implementation of a scooter share scheme.
Emerg Med Australas. 2019;31(6):930-934 - PMID: 31423709 - DOI: 10.1111/1742-6723.13356
Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma.
Oncogene. 2019;38(18):3504-3520 - PMID: 30651601 - PMCID: PMC6756020 - DOI: 10.1038/s41388-018-0632-2
Use of Targeted Next-Generation Sequencing to Identify Activating Hot Spot Mutations in Cherry Angiomas.
JAMA Dermatol. 2019;155(2):211-215 - PMID: 30601876 - PMCID: PMC6440195 - DOI: 10.1001/jamadermatol.2018.4231
Number needed to screen for presumptive screening diagnoses among first-time SPOTme screening participants (1992-2010).
J Am Acad Dermatol. 2019;82(1):233-234 - PMID: 31228527 - PMCID: PMC7985849 - DOI: 10.1016/j.jaad.2019.06.027
Case-control analysis identifies shared properties of rare germline variation in cancer predisposing genes.
Eur J Hum Genet. 2019;27(5):824-828 - PMID: 30718883 - PMCID: PMC6461796 - DOI: 10.1038/s41431-019-0346-0
Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum.
Br J Dermatol. 2019;181(5):1095-1097 - PMID: 31102460 - DOI: 10.1111/bjd.18144
In vivo coherent Raman imaging of the melanomagenesis-associated pigment pheomelanin.
50

